The future of personalising myeloma care in the UK: empowering shared decision-making
Published:
MOSAIC provides an opportunity to better understand current diagnostic pathways and access across the UK. In practical terms, the study will help test how deliverable IMS/IMWG-compliant genomic testing and PRD/MRD testing are within the NHS, provide clinicians with additional diagnostic information, and build familiarity with these technologies in a way that can support future clinical use.
Sign up and become a member of the Myeloma UK HCP Hub
Access exclusive content like this and join in the conversation.
Already have an account?